Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.
Endocrine therapy remains important in premenopausal women with hormone receptor positive breast cancer. Ovarian ablation, used alone, is effective in delaying recurrence and increasing survival in such women. When added to chemotherapy, it is less clear that it is effective perhaps because of the endocrine ablative effect of chemotherapy. Trials comparing ovarian ablation with or without tamoxifen to CMF-type chemotherapy suggest that the endocrine therapy is equivalent to or better than this chemotherapy in women whose tumors have estrogen and/or progesterone receptor. Tamoxifen is also effective in preventing recurrence and prolonging survival in the adjuvant setting in premenopausal women. While most of the available data deals with tamoxifen given alone, it appears to have a similar beneficial effect when added to chemotherapy in the premenopausal adjuvant setting. Adjuvant aromatase inhibitors should not be used in premenopausal women.
Pritchard
Kathleen
K
Breast Cancer Site Group, Toronto Sunnybrook Regional Cancer Centre, Canada. kathy.pritchard@sw.ca <kathy.pritchard@sw.ca>
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D009364:Neoplasm Recurrence, Local; D017697:Premenopause; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013534:Survival; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone
J Clin Oncol. 2001 Jan 15;19(2):343-53
11208825
J Clin Oncol. 2003 Feb 1;21(3):453-7
12560434
J Clin Oncol. 1998 Aug;16(8):2651-8
9704715
Trans Med Chir Soc Edinb. 1896;15:153-179
29584099
N Engl J Med. 1988 Dec 29;319(26):1681-92
3205265
J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60
9747866
Br J Cancer. 1988 Jun;57(6):608-11
2900647
Br Med J. 1973 Jan 6;1(5844):13-4
4567104
J Clin Oncol. 1998 Feb;16(2):470-9
9469330
J Clin Oncol. 2001 Sep 15;19(18):3808-16
11559718
J Clin Oncol. 2002 Mar 15;20(6):1467-72
11896093
Lancet. 1985 Jan 5;1(8419):16-9
2856949
Cancer Treat Rep. 1980 Jun-Jul;64(6-7):787-96
7427962
Lancet. 1998 May 16;351(9114):1451-67
9605801
N Engl J Med. 1989 Feb 23;320(8):479-84
2644532
J Clin Oncol. 2002 Dec 15;20(24):4628-35
12488406
Eur J Cancer. 1999 Nov;35(12):1625-7
10674005
Br J Cancer. 1988 Jun;57(6):601-3
3044432
Lancet. 1987 Jul 25;2(8552):171-5
2885637
J Clin Oncol. 1992 Apr;10(4):599-605
1548522
Eur J Cancer. 1999 Nov;35(12):1659-66
10674010
J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8
11121461
J Clin Oncol. 1992 Jul;10(7):1049-56
1351538
Eur J Cancer. 1991;27(8):966-70
1832904
J Clin Oncol. 1998 Mar;16(3):994-9
9508182
J Clin Oncol. 2000 Jul;18(14):2718-27
10894871
Lancet. 1992 Jan 11;339(8785):95-6
1345872
J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70
9747867
Lancet. 1993 May 22;341(8856):1293-8
8098446
Lancet. 1992 Jan 11;339(8785):71-85
1345869
J Clin Oncol. 2002 Dec 15;20(24):4611-4
12488402
Ann Oncol. 2001 Aug;12(8):1081-9
11583189
Eur J Cancer. 2007 Jan;43(2):331-40
17134892
J Clin Oncol. 2002 Dec 15;20(24):4621-7
12488405